Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conversion from standard phosphate binders to Fosrenol in CKD stage 5 haemodialysis patients
2006-003364-64Phase 4Terminated
- Sponsor
- Takeda
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lanthanum carbonate in hyperphosphatemia, end-stage kidney disease (ESKD) and chronic kidney disease (CKD), sponsored by Takeda. Primary endpoint: Serum phosphorus control at week 12 after conversion to Fosrenol. Started Jan 2007; status: terminated.
02
Drugs
lanthanum carbonate
03
Conditions
hyperphosphatemiaend-stage kidney disease (ESKD)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2006-003364-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003364-64.